We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+11.13%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
-$123M
Cap. Flow
-$193M
Cap. Flow %
-4.9%
Top 10 Hldgs %
32.83%
Holding
121
New
17
Increased
40
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
SGRY icon
Surgery Partners
SGRY
+$30.8M
2
LLY icon
Eli Lilly
LLY
+$24M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$20.7M
4
PHVS icon
Pharvaris
PHVS
+$20M
5
OSCR icon
Oscar Health
OSCR
+$18.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$163M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$89.3M
3
HUM icon
Humana
HUM
+$61.6M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$49.1M
5
BPMC
Blueprint Medicines
BPMC
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Consumer Staples 1.95%
3 Industrials 0.94%
4 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOCL
76
EDAP TMS S.A.
FOCL
$231M
$10.8M 0.28%
1,475,000
+88,575
+6% +$572K
MLYS icon
77
Mineralys Therapeutics
MLYS
$2.41B
$10.2M 0.26%
792,615
-374,877
-32% -$4.63M
APLT
78
DELISTED
Applied Therapeutics
APLT
$10.2M 0.26%
1,497,918
+602,723
+67% +$2.71M
NUVL
79
DELISTED
Nuvalent
NUVL
$9.41M 0.24%
+125,302
New +$9.97M
ABOS icon
80
Acumen Pharmaceuticals
ABOS
$179M
$9.32M 0.24%
2,300,059
– –
IMTX icon
81
Immatics
IMTX
$1.33B
$8.92M 0.23%
848,751
-1,026,715
-55% -$12M
NMRA icon
82
Neumora Therapeutics
NMRA
$308M
$8.88M 0.23%
+646,118
New +$10.4M
ELVN icon
83
Enliven Therapeutics
ELVN
$4.29B
$7.54M 0.19%
+428,571
New +$6.58M
CGON icon
84
CG Oncology
CGON
$6.79B
$7.5M 0.19%
+170,859
New +$6.98M
BHVN icon
85
Biohaven
BHVN
$2.14B
$6.94M 0.18%
+126,984
New +$6.29M
FULC icon
86
Fulcrum Therapeutics
FULC
$285M
$6.87M 0.17%
727,673
– –
AUTL
87
Autolus Therapeutics
AUTL
$599M
$6.59M 0.17%
+1,032,988
New +$6.44M
LUNG icon
88
Pulmonx
LUNG
$101M
$6.05M 0.15%
652,400
– –
AUPH icon
89
Aurinia Pharmaceuticals
AUPH
$2.06B
$5.76M 0.15%
1,150,347
+737,777
+179% +$5M
EPIX
90
DELISTED
ESSA Pharma
EPIX
$5.75M 0.15%
677,005
– –
PLRX icon
91
Pliant Therapeutics
PLRX
$65.6M
$5.74M 0.15%
384,996
– –
BEAM icon
92
Beam Therapeutics
BEAM
$2.8B
$4.87M 0.12%
147,510
+36,080
+32% +$1.12M
ALNY icon
93
CALL
Alnylam Pharmaceuticals
ALNY
$29.4B
$4.86M 0.12%
+32,500
New +$5.42M
VINC
94
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$4.51M 0.11%
44,586
– –
KYTX icon
95
Kyverna Therapeutics
KYTX
$488M
$4.45M 0.11%
+178,963
New +$4.99M
SGMT icon
96
Sagimet Biosciences
SGMT
$588M
$4.18M 0.11%
770,671
+32,316
+4% +$232K
GOSS icon
97
Gossamer Bio
GOSS
$90.2M
$3.86M 0.1%
3,266,960
– –
ADAP
98
DELISTED
Adaptimmune Therapeutics
ADAP
$3.83M 0.1%
2,425,468
– –
ACRS icon
99
Aclaris Therapeutics
ACRS
$873M
$3.41M 0.09%
2,753,495
-245,000
-8% -$292K
CGEN icon
100
Compugen
CGEN
$225M
$3.33M 0.08%
1,289,990
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rock Springs Capital Management held 121 positions worth $3.94B, down 3% from $4.06B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $193M in Q1 2024, closing 7 positions and reducing 11 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $163M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Surgery Partners worth $29.4M.

  • Rock Springs Capital Management's largest Q1 2024 buy was Surgery Partners: 985,000 shares worth $29.4M.
  • Rock Springs Capital Management added most to Eli Lilly in Q1 2024, an estimated $24M increase.
  • Rock Springs Capital Management's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $89.3M.
  • Rock Springs Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $163M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $3.94B portfolio in Q1 2024.
  • Rock Springs Capital Management opened 17 new positions and closed 7 in Q1 2024.
  • Rock Springs Capital Management's portfolio value fell 3% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.